NuCana Stock Soars 151% on Upbeat Efficacy Data From …
WEB3 days ago · NCNA. Shares of NuCana plc NCNA skyrocketed 150.8% on Monday after the announcement of encouraging final data from the mid-stage study of its investigational candidate, NUC-7738, in combination ...
NuCana's Encouraging Data From Resistant Melanoma Treatment …
WEB4 days ago · On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's (NYSE:MRK) Keytruda ...
NuCana Presents Encouraging Data on NUC-7738 in Combination …
WEBSep 14, 2024 · NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.
NuCana soars on positive data from mid-stage trial for its …
WEB4 days ago · NuCana plc (NASDAQ: NCNA) shares more than doubled premarket by almost 160% after its data from a mid-stage trial for its metastatic melanoma treatment, which was presented at the ESMO Congress ...
NuCana's Encouraging Data From Resistant Melanoma Treatment …
WEB4 days ago · NuCana presented final data from a Phase 2 study at ESMO Congress, showing NUC-7738 combined with Keytruda achieved a 75% disease control rate in metastatic melanoma patients resistant to prior PD ...
NuCana soars on positive data from mid-stage trial for its ... - MSN
WEB4m. NuCana plc (NASDAQ: NCNA) shares more than doubled premarket by almost 160% after its data from a mid-stage trial for its metastatic melanoma treatment, which was presented at the ESMO ...
NuCana Presents Encouraging Data on NUC-7738 in
WEBSep 14, 2024 · NuCana’s pipeline includes NUC-3373 and NUC-7738. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent. NUC-3373 is currently ...
NuCana ADRs Nearly Double on Positive Data From
WEB5 days ago · NuCana's American depositary receipts nearly doubled on Monday after the company reported positive data for its metastatic melanoma treatment. In premarket trading ADRs were up $2.44 to $4.98 ...
News Releases | Investor Relations - NuCana plc
WEBMay 21, 2024 · NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
NuCana Presents Encouraging Data on NUC-7738 in Combination …
WEB6 days ago · NuCana’s pipeline includes NUC-3373 and NUC-7738. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent.